Eli Lilly Is Printing Money and the Market Hasn't Fully Caught On

Signal: BUY | Score: 65.36/100

Lilly just reported 48% revenue growth, raised full-year guidance to $85-87 billion, secured coverage from all three major U.S. PBMs for its obesity drugs, and the stock is still sitting 9% below its 52-week high. That's the kind of setup that gets attention. With earnings just 20 days away and a momentum score of 70, the window to get positioned is closing fast.

The Setup

LLY is trading at $1,176, well off its $1,292 peak but firmly above the $783 low it set earlier this year. The RSI sits at 53.4, which means this is not overbought territory - it's mid-range, with room to run. The stock bounced 4.1% to a record high after the PBM coverage news in early October, showing there's real buying conviction here. Technical score comes in at 62.6, which reflects a healthy trend continuation setup rather than a speculative breakout. The beta of 0.45 also tells you this is a smoother ride than most mega-cap growth names.

The Catalyst

Three things are working in LLY's favor right now, and they're all happening at once. First, CVS Caremark restored Zepbound coverage on October 1 and began covering the oral GLP-1 Foundayo on June 1 - all three major PBMs are now on board. That removes one of the biggest commercial friction points for the entire obesity drug business. Second, Q2 revenue hit $23 billion with Mounjaro pulling in $9.94 billion alone, and management raised guidance to $85-87 billion for the full year. Third, the FDA approved once-weekly insulin Onswik, the company signed a $3.35 billion InnoCare licensing deal, and Phase 3 data for retatrutide is pointing toward a 2027 filing. The pipeline is not slowing down.

Bull Case

Analysts have a consensus target of $1,330, representing 13% upside from current prices - and that estimate is likely to move higher after the October 29 earnings call
Forward PE of 24.7x on a company growing revenue at 48% year over year gives you a PEG ratio of just 1.13 - that's not expensive for this growth profile
Broader GLP-1 reimbursement is a volume story, and volume is just starting to scale

Bear Case

Debt-to-equity at 162 is elevated and worth watching as rates evolve
Novo Nordisk and emerging competitors remain a real threat, and any clinical setback for retatrutide would sting the valuation

The Trade

Entry: $1,176
Target: $1,330 (analyst consensus, near 52-week high)
Stop Loss: $1,080 (below recent consolidation base)
Risk/Reward: 1:1.6
Timeframe: 4-8 weeks, with the October 29 earnings as the primary catalyst event

*This is one person's analysis, not financial advice. Always do your own research.*